Advanced Search
DSpace@MIT

Feature-based investment cost estimation based on modular design of a continuous pharmaceutical manufacturing system

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Bernhardt Trout and Charlie Fine. en_US
dc.contributor.author Collins, Donovan (Donovan Scott) en_US
dc.contributor.other Leaders for Global Operations Program. en_US
dc.date.accessioned 2011-09-27T18:38:29Z
dc.date.available 2011-09-27T18:38:29Z
dc.date.issued 2011 en_US
dc.identifier.uri http://hdl.handle.net/1721.1/66063
dc.description Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering; in conjunction with the Leaders for Global Operations Program at MIT, June 2011. en_US
dc.description "June 2011." Cataloged from PDF version of thesis. en_US
dc.description Includes bibliographical references (p. 72-73). en_US
dc.description.abstract Previous studies of continuous manufacturing processes have used equipment-factored cost estimation methods to predict savings in initial plant investment costs. In order to challenge and validate the existing methods of cost estimation, feature-based cost estimates were constructed based on a modular process design model. Synthesis of an existing chemical intermediate was selected as the model continuous process. A continuous process was designed that was a literal, step by step, translation of the batch process. Supporting design work included process flow diagrams and basic piping and instrumentation diagrams. Design parameters from the process model were combined with feature-based costs to develop a series of segmented cost estimates for the model continuous plant at several production scales. Based on this analysis, the continuous facility seems to be intrinsically less expensive only at a relatively high production scale. Additionally, the distribution of cost areas for the continuous facility differs significantly from the distribution previous assumed for batch plants. This finding suggests that current models may not be appropriate for generating cost estimates for continuous plants. These results should not have a significant negative impact on the value proposition for the continuous manufacturing platform. The continuous process designed for this project was not optimized. Therefore, this work reiterates that the switch to continuous must be accompanied with optimization and innovation in the underlying continuous chemistry. en_US
dc.description.statementofresponsibility by Donovan Collins. en_US
dc.format.extent 73 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri http://dspace.mit.edu/handle/1721.1/7582 en_US
dc.subject Sloan School of Management. en_US
dc.subject Chemical Engineering. en_US
dc.subject Leaders for Global Operations Program. en_US
dc.title Feature-based investment cost estimation based on modular design of a continuous pharmaceutical manufacturing system en_US
dc.type Thesis en_US
dc.description.degree S.M. en_US
dc.description.degree M.B.A. en_US
dc.contributor.department Sloan School of Management. en_US
dc.contributor.department Massachusetts Institute of Technology. Dept. of Chemical Engineering. en_US
dc.contributor.department Leaders for Global Operations Program. en_US
dc.identifier.oclc 753704109 en_US


Files in this item

Name Size Format Description
753704109.pdf 4.081Mb PDF Preview, non-printable (open to all)
753704109-MIT.pdf 4.081Mb PDF Full printable version (MIT only)

This item appears in the following Collection(s)

Show simple item record

MIT-Mirage